The result of this finding suggested a possible use of S6K1 inhibitor together with bevacizumab (anti-VEGF antibody) for regulating immune response against HCC and immunotherapeutic approaches for HCC 28, 29. Here, RPS6KB1 is linked to hepatocellular carcinoma.